NCT05397496 - Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

June 7, 2027

Study Completion Date

June 5, 2028

Conditions

B-cell Non-Hodgkin Lymphoma (B-NHL)B-cell Acute Lymphoblastic Leukemia (B-ALL)

Interventions

BIOLOGICAL

PIT565

Intravenous (i.v.) infusion or Subcutaneous (s.c.) injection

Trial Locations (21)

9000

RECRUITING

Novartis Investigative Site, Ghent

10065

RECRUITING

Memorial Sloan Kettering Cancer Ctr, New York

13273

RECRUITING

Novartis Investigative Site, Marseille

20089

RECRUITING

Novartis Investigative Site, Rozzano

20133

WITHDRAWN

Novartis Investigative Site, Milan

33136

RECRUITING

University Of Miami, Miami

40138

WITHDRAWN

Novartis Investigative Site, Bologna

42123

RECRUITING

Novartis Investigative Site, Reggio Emilia

60637

RECRUITING

University of Chicago Medical Center, Chicago

66205

RECRUITING

The University of Kansas Clinical Research Ctr, Fairway

94010

RECRUITING

Novartis Investigative Site, Créteil

97239

RECRUITING

Oregon Health Sciences University, Portland

100730

RECRUITING

Novartis Investigative Site, Beijing

119074

RECRUITING

Novartis Investigative Site, Singapore

169608

RECRUITING

Novartis Investigative Site, Singapore

200032

RECRUITING

Novartis Investigative Site, Shanghai

300020

RECRUITING

Novartis Investigative Site, Tianjin

6423906

RECRUITING

Novartis Investigative Site, Tel Aviv

277 8577

RECRUITING

Novartis Investigative Site, Kashiwa

08035

RECRUITING

Novartis Investigative Site, Barcelona

08036

RECRUITING

Novartis Investigative Site, Barcelona